Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

Cipla, a global pharmaceutical leader, has partnered with ImmunoACT to introduce talicabtagene autoleucel in Africa. This is ...

Editing CAR T cells to produce inflammatory cytokines helps them enter solid tumors and promote cancer killing.

The panel discussion, “Innovations in Breast Cancer Treatment,” examined the challenge of maintaining or increasing access to care as breast cancer treatment becomes more stratified through biomarker ...

At study entry, patients demonstrated immune compromise consistent with prior standard of care, including radiation and alkylating chemotherapy. The baseline mean absolute lymphocyte count (ALC) was ...

Amid growing evidence suggesting circadian rhythms play a critical in the safety and efficacy of CAR T-cell therapy, ...

A new partnership between The Ottawa Hospital and the University of Ottawa will help make Canada more self-reliant in the ...

GSK is set to buy Rapt Therapeutics in a $2.2 billion deal. AstraZeneca agreed to a $630 million pact to secure remaining rights to armored CAR-T from AbelZeta. Bristol Myers Squibb signed a deal with ...

Just outside Minneapolis, the Whipple Building houses offices, a detention center and a courthouse — and has become the home ...

Bitter cold, power outages, and impassible roads are a terrible cocktail. Here’s how to prep and bunker in for an extreme ...

Blood transfusions are essential for patients with cancer, sickle cell disease, and traumatic injuries, but blood supply ...